Jim Simons’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Jim Simons’s Portfolio TMBR Stock Details TMBR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,700	Closed	-$30K	–	4453
2023 Q1	$30K	Buy	+17,700	New	+$40.1K	﹤0.01%	3762
2022 Q3	–	Sell	-316	Closed	-$5K	–	4546
2022 Q2	$5K	Sell	316 -17,109	-98%	-$249K	﹤0.01%	4171
2022 Q1	$335K	Buy	17,425 +4,774	+38%	+$79.6K	﹤0.01%	3420
2021 Q4	$240K	Buy	+12,651	New	+$359K	﹤0.01%	3439
2021 Q3	–	Sell	-2,376	Closed	-$145K	–	3984
2021 Q2	$145K	Buy	+2,376	New	+$167K	﹤0.01%	3311
2020 Q1	–	Sell	-48	Closed	-$12K	–	3931
2019 Q4	$12K	Buy	+48	New	+$9.35K	﹤0.01%	3464
2019 Q1	–	Sell	-37	Closed	-$59K	–	3778
2018 Q4	$59K	Buy	+37	New	+$87.7K	﹤0.01%	3280

Other funds holding TMBR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CPG

Cornerstone Planning Group Fairfield, New Jersey $794M AUM 22.68% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Jim Simons's TMBR Position: Q2 2023 in Review

Jim Simons sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q2 2023, closing a stake of 17,700 shares — an estimated $30K sold.

Jim Simons first reported a position in TMBR in Q4 2018 and held it in 7 quarters. The position peaked at $335K in Q1 2022. 9 funds tracked by Wall St. Rank hold TMBR as of Q2 2023.

Jim Simons reported no remaining Timber Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Jim Simons sold 17,700 Timber Pharmaceuticals, Inc. shares in Q2 2023, an estimated $30K.
Jim Simons first reported a position in Timber Pharmaceuticals, Inc. in Q4 2018 and held it in 7 quarters.
Jim Simons's Timber Pharmaceuticals, Inc. position peaked at $335K in Q1 2022.
9 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.